Gilead Sciences Inc. (GILD)
NASDAQ: GILD
· Real-Time Price · USD
110.02
-1.09 (-0.98%)
At close: May 30, 2025, 3:59 PM
110.26
0.22%
After-hours: May 30, 2025, 05:57 PM EDT
Gilead Sciences Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| Cell Therapy Products, Total Cell Therapy Product Sales Revenue | 2.38B | 2.24B | 1.76B | 1.05B | 607M | 47M | 61M |
| Cell Therapy Products, Total Cell Therapy Product Sales Revenue Growth | +6.12% | +27.36% | +67.91% | +72.49% | +1191.49% | -22.95% | n/a |
| Products, Other HIV Revenue | 19.61B | 859M | 946M | 1.03B | 1.89B | n/a | n/a |
| Products, Other HIV Revenue Growth | +2183.12% | -9.20% | -7.89% | -45.55% | n/a | n/a | n/a |
| Other Products, Total Other product sales Revenue | 889M | 18.23B | 17.25B | 16.36B | 17B | n/a | n/a |
| Other Products, Total Other product sales Revenue Growth | -95.12% | +5.68% | +5.41% | -3.71% | n/a | n/a | n/a |
| Trodelvy Revenue | 1.31B | 1.06B | 680M | 380M | n/a | n/a | n/a |
| Trodelvy Revenue Growth | +23.71% | +56.32% | +78.95% | n/a | n/a | n/a | n/a |
| Veklury Revenue | 1.8B | 2.18B | 3.9B | 5.57B | n/a | n/a | n/a |
| Veklury Revenue Growth | -17.63% | -44.07% | -29.83% | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe Revenue | 4.63B | 4.31B | 4.47B | 4.87B | 4.13B | 3.81B | 4.01B | 5.31B | 6.37B | 7.53B | 5.44B | 3.61B | 3.33B | 4.61B | 4.22B |
| Europe Revenue Growth | +7.52% | -3.56% | -8.31% | +17.87% | +8.50% | -4.87% | -24.57% | -16.56% | -15.45% | +38.33% | +50.61% | +8.42% | -27.68% | +9.10% | n/a |
| United States Revenue | 20.59B | 19.44B | 18.88B | 19.27B | 18.22B | 16.64B | 16.27B | 18.19B | 19.35B | 21.23B | 18.18B | 6.7B | 5.59B | n/a | n/a |
| United States Revenue Growth | +5.93% | +2.93% | -1.99% | +5.76% | +9.44% | +2.31% | -10.58% | -5.99% | -8.85% | +16.79% | +171.57% | +19.73% | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.26B | 1.91B | 1.43B | 1.38B | 1.38B | 1.61B | 1.31B | 1.85B | 1.32B | 2.02B | 1.21B | 1.36B | 1.08B | 1.65B | 1.19B | 1.35B | 1.05B | 1.73B | 1.11B | 1.24B | 1.08B | 1.2B | 1.05B | 1.09B | 1.03B | 1.13B | 948M | 980M | 997M | 1.25B | 879M | 897M | 850M | 992M | 831M | 890M | 685M | 1.07B | 903M | 812M | 645M |
| Selling, General, and Administrative Revenue Growth | -34.03% | +33.08% | +4.07% | +0.15% | -14.49% | +22.28% | -28.88% | +40.18% | -34.70% | +66.53% | -10.61% | +25.30% | -34.36% | +38.66% | -11.92% | +28.06% | -39.02% | +56.42% | -10.73% | +15.15% | -10.63% | +14.45% | -3.93% | +6.31% | -8.93% | +19.30% | -3.27% | -1.71% | -20.37% | +42.43% | -2.01% | +5.53% | -14.31% | +19.37% | -6.63% | +29.93% | -35.74% | +18.05% | +11.21% | +25.89% | n/a |
| Research and Development Revenue | 1.38B | 1.64B | 1.4B | 1.35B | 1.52B | 1.41B | 1.46B | 1.41B | 1.45B | -1.15B | 1.15B | 1.1B | 3.88B | 2.03B | 1.1B | 1.09B | 1.05B | 1.58B | 1.16B | 1.3B | 1B | 1.9B | 1.03B | 995M | 1.06B | 1.95B | 939M | 1.19B | 937M | 1.15B | 789M | 864M | 931M | 1.21B | 1.14B | 1.48B | 1.26B | 757M | 743M | 818M | 696M |
| Research and Development Revenue Growth | -15.97% | +17.63% | +3.26% | -11.12% | +7.95% | -3.36% | +3.55% | -2.76% | -225.61% | -200.26% | +4.26% | -71.58% | +91.32% | +84.11% | +0.82% | +3.51% | -33.14% | +36.27% | -10.85% | +29.38% | -47.13% | +84.37% | +3.52% | -5.87% | -45.79% | +107.67% | -21.22% | +27.21% | -18.52% | +45.75% | -8.68% | -7.20% | -22.93% | +5.87% | -23.11% | +17.31% | +67.11% | +1.88% | -9.17% | +17.53% | n/a |
| Sales and Marketing Revenue | 753M | n/a | n/a | n/a | 743M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue Growth | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |